^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Solid Tumor
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

    Excerpt:
    ......
    Trial ID:
    METROS
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Crizotinib for ROS1 and MET Activated Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT04084717
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT03088930
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

    Published date:
    05/25/2023
    Excerpt:
    We demonstrate clinical activity using crizotinib across tumors in patients with METamp and METex14. In METex14, differentiating true pathogenic variants from low-level splice variant transcripts may be clinically meaningful. Clinical trial information: NCT02465060.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3108
    Trial ID:
    NCI-MATCH